As a prerequisite for a human clinical trial using interleukin (IL)-12 gene therapy, the biodistribution and safety of IL-12, administered as an intradermal naked DNA injection, was evaluated in mice. The pNGVL3-mIL12 plasmid used in this study is a nonviral vector designed to induce a high level of IL-12 protein expression during a transient transfection of the host cell. The biodistribution was evaluated by a polymerase chain reaction (PCR) assay that is capable of detecting less than 100 copies of the plasmid in the context of host DNA. Twenty-four hours after three intradermal injections of 0.5 mg or 5 mg of pNGVL3-mIL12 plasmid, the plasmid was detectable in various internal organs, the blood, and the injection site. The plasmid was detectable in the gonads of only one animal at the high-dose treatment 24 hr after the injections. In the majority of the organs the plasmid was undetectable throughout the study. Possible side effects were monitored by histology and clinical chemistry, and the level of IL-12 protein expression was assessed by enzyme-linked immunosorbent assay (ELISA). No treatment-related histologic abnormalities were detected and the blood chemistry parameters showed no toxicity. The IL-12 protein was undetectable at all times at the injection site and interferon (IFN)-g levels at the injection site and in the serum were at background levels. The results of this murine safety study indicate that based on the distribution pattern of the plasmid in the body and the undetectable toxicities in the tissues, the use of the pNGVL3-hIL12 plasmid in cancer gene therapy clinical trials can be considered as safe.
INTRODUCTION I
N RECENT YEARS, interleukin (IL)-12 has become one of the most efficient antitumor cytokines in experimental animal models. Initial studies using systemic treatment with recombinant IL-12 protein, both in animal models (Orange et al., 1995) and human clinical trials (Marshall, 1995; Jenks, 1996) resulted in discouraging dose-limiting toxicities. In comparative studies using IL-12 gene therapy and IL-12 protein therapy against various tumors in mice, the IL-12 gene therapy proved to be as efficient as the IL-12 protein therapy but it induced far less toxic side effects (Rakhmilevich et al., 1999) . The lack of severe side effects of IL-12 gene therapy, suggests it may be a safer alternative to IL-12 protein therapy for certain human cancers. The preclinical studies we conducted using intratumoral IL-12 gene therapy showed that this treatment can induce a striking antitumor response in various murine tumor models including melanoma, sarcoma and adenocarcinoma (Rakhmilevich et al., 1997 (Rakhmilevich et al., , 1999 (Rakhmilevich et al., , 2000 Weber et al., 1999) . For these studies the IL-12 cDNA was delivered by particle-mediated gene transfer. We have recently explored intratumoral naked DNA injections against the weakly immunogenic CT26 adenocarcinoma using the identical vectors that were used for the particle-mediated gene transfer. These studies have shown that the antitumor effect of naked IL-12 cDNA is comparable to the particle mediated route of administration when roughly 40 times higher doses of naked DNA (50 mg) were used compared to the doses used for the particle mediated administration (unpublished data). The clinical simplicity and adaptability of using naked DNA administered by needle and syringe, makes IL-12 gene therapy an even more attractive candidate for clinical testing in the treatment of certain human cancers. An additional advantage of the murine IL12 cDNA plasmid (pNGVL3-mIL12) that we used is that it is a nonviral, high copy number plasmid designed to achieve a transient transfection of the host cell and a high level of IL-12 protein expression.
Based on our findings of antitumor efficacy using the naked DNA intratumoral administration of IL-12 cDNA in murine tumor models, we have proposed a clinical study. Patients in group 1 of this proposed trial will have subcutaneous metastases treated with 50 mg of pNGVL3-mIL12 plasmid given every other day for three treatments. For patients in group 2, a second identical segment of three treatments would be repeated 2 days after completing the first three treatments. Because of the toxic side effects experienced with the IL-12 protein when given as systemic treatment, thorough preclinical testing of the biodistribution and safety of the naked DNA administration is required prior to initiating a clinical trial. In particular the distribution and persistence of the plasmid throughout the body, especially in the gonads of high-dose-treated animals require analysis. We have designed preclinical experiments to answer questions raised by the National Cancer Institute and the U.S. Food and Drug Administration regarding safety and DNA biodistribution relative to the abovementioned clinical trial we plan to conduct. The murine studies presented in this report were designed to mimic as closely as possible the proposed human study. Mice were given 0.5 mg or 5 mg of pNGVL3-mIL12 plasmid subcutaneously. The amount of plasmid DNA (0.5 mg or 5 mg) relative to the body weight given to the mice was 400 to 4000 times greater than the dose that had been proposed for the human study. This dosing pattern has built into the biodistribution study an extensive margin of safety for the detection of possible side effects of this gene therapy. A protocol similar to the group 1 patients was chosen.
MATERIALS AND METHODS

Animals
NIH Swiss outbred male (24-34 g weight class) and female (retired breeder, 351 g) mice were obtained from Harlan (Indianapolis, IN). Animals were housed in an American Association for the Accreditation of Laboratory Animal Care-accredited facility under isothermal conditions in microisolators and allowed access to food and water ad libitum.
Plasmid
The murine interleukin-12 (mIL-12) expression plasmid pNGVL3-mIL12 was constructed using a cytomegalovirus (CMV) early enhancer/promoter/intron-based plasmid with a kanamycin selection gene. The p35 and p40 subunits were separated by an internal ribosomal entrance site and driven by a single CMV promoter (National Gene Vector Laboratory, University of Michigan, Ann Arbor, MI). The pNGVL3-mIL12 plasmid was transfected into Escherichia coli and kanamycinresistant clones were selected for expansion in overnight cultures. From these cell cultures the pNGVL3-mIL12 plasmid was purified using the Qiagen Midi preparation kit (Qiagen, Valencia, CA) according to the manufacturers guidelines. Purified plasmid was then quantified photospectrometrically (UV absorbance at 260 nm) and tested for its biofunctionality in vivo against intradermal CT26 tumors in BALB/c mice. Briefly, tumors were established using intradermal injection of 1 3 10 5 CT26 tumor cells. Usually on day 6 after tumor injection the first intratumoral injection of 25-50 mg pNGVL3-mIL12 plasmid or control plasmid without an insert was performed. Treatments were repeated on day 8 and day 10. Tumor growth was monitored for 30 days. Typically this treatment regimen resulted in 4 of 5 mice with complete regression of their intradermal tumors.
Injections
Groups of mice received a single injection of either 0.5 mg or 5 mg of pNGVL3-mIL12 in a volume of 100 ml phosphatebuffered saline (PBS) or PBS alone. The injection side (dorsal) was shaven prior to the injection and the injection was performed intradermally using a 30-gauge needle. For this procedure the first two animals of the PBS control group were restrained in a mouse restrainer to perform the injection; all other animals were transiently anesthetized to allow maximal precision of the injection. At the indicated time points, the mice were sacrificed through retro-orbital bleeding under anesthesia; the blood was collected in heparinized tubes.
Tissue collection
For each animal sacrificed through bleeding, blood was collected and then 10 additional tissue samples were taken from distinct sites. Brain, gonads, and bone marrow were collected first, followed in order by the collection of spleen, kidney, liver, lung, heart, and lymph nodes, followed by harvesting the skin containing the injection site. To avoid cross-contamination between different organs three sets of instruments were used for each animal. A different set of instruments was used for each day of collection. On collection, the organs were divided into DNA samples and histopathology samples. All organ samples from one animal were combined in one collection cassette and fixed in neutral buffered 10% formalin solution immediately after collection. The bone sample was first decalcified for 24 hr (Cal-Ex, Fisher Chemical, Pittsburgh, PA) and then processed with the other samples. Briefly, the samples were passed through a graded series of ethanol to xylene, followed by infiltration and embedment in TissuePrep media (Fisher). Multiple 5-mm thick sections were cut and at least two sections from each block were stained with hematoxylin and eosin for histologic examination.
For most DNA extractions, 50-100 mg pieces of tissue were used for the extraction. For the bone marrow DNA extraction, bone marrow tissue was removed from the shaft of the contralateral femur and both tibias by pressurized flushing with RPMI culture medium using a fresh syringe and needle for each animal. For lymph node DNA extraction, the remaining axillary lymph node plus the inguinal lymph nodes (on the ipsilateral side as the DNA injections) were processed.
For the IL-12 and interferon (IFN)-g detection, samples were processed as follows. The skin was cut into small pieces, and 0.5 ml of RPMI was added, the samples were sonicated for 30 sec, and after centrifugation at 14000 rpm in a microcentrifuge, the supernatant was collected and stored at 220°C for subsequent analysis by enzyme-linked immunosorbent assay (ELISA). Blood plasma was obtained from heparinized whole blood that was collected by retro-orbital bleeding.
DNA preparation
The DNA preparation was done using the High Pure PCR Template Preparation Kit from Roche Diagnostics Corporation (Indianapolis, IN). This DNA preparation kit is designed to achieve highly pure total genomic DNA from cells or tissue samples. The kit was used according to the manufacturer's instructions including an additional, optional purification step to remove components such as heparin that are known to interfere with the PCR reaction. Eluted DNA was diluted 1:20 and A 260 was determined spectrophotometrically.
In order to test the kit's ability to capture free plasmid, 100 and 1000 copies of pNGVL3-mIL12 plasmid per microgram of expected DNA yield were added to approximately 50 mg of liver tissue prior to the purification. The DNA purification was then carried out as described above and the DNA tested in a PCR assay.
ELISA
The ELISA assay to detect IFN-g in serum or tissue supernatant was carried out according to standard protocols. Rat antimouse IFN-g antibody (2 mg/ml, BD Pharmingen, San Diego, CA) coated plates were incubated with 50 ml of 1:20 diluted serum samples or tissue supernatant samples. Biotinylated rat anti-mouse IFN-g and streptavidin-horseradish peroxidase (HRP) were used for detection and dual wavelength at 450 nm and 570 nm for the read out in a Spectra Classic ELISA reader (Tecan, Austria). The standard used was recombinant mouse IFN-g (BD Pharmingen) ranging from 7.8 pg/ml to 500 pg/ml. The assay to detect mouse IL-12 was done using a detection kit from Biosource International, Inc. (Camarillo, CA) according to the instructions. Statistical comparisons between the samples were done using Student's t test.
PCR
The MacVector software (Accelrys, San Diego, CA) was used to design primers that amplify a sequence stretch that contains plasmid-specific promoter sequence (CMV) as well as mIL-12 sequence from the p35 subunit. The resulting pNGVL3-mIL12 plasmid specific product that is generated is 784 bp in length. The optimal PCR conditions determined were: annealing temperature 58°C for 45 sec, extension 72°C for 90 sec, denaturation 94°C for 45 sec. The sequences for the primers are: 59-GATGCGGTTTTGGCAGTACATC-3 9 sense, 59-TGTGG-TCTTCAGCAGGTTTCG-3 9 antisense. By using these conditions we were able to detect 25 copies of pNGVL3-mIL12 plasmid per PCR reaction. To confirm the specificity of the primers for the pNGVL3-mIL12 plasmid, irrelevant cDNA derived from murine cell lines or murine tissue was tested in a PCR using these primers.
In general, 1 mg of DNA per sample was tested in the PCR assay and all the samples were run in triplicates. In parallel, separate 1-mg aliquots of each DNA sample were mixed with 100 and 1000 copies of pNGVL3 plasmid, to test the sensitivity of the PCR at detecting the pNGVL3 plasmid in conjunction with that particular DNA. In cases where the total DNA yield was insufficient to test the sample in triplicate plus the separate samples to which 1000 and 100 copies of plasmid were added, the amount of DNA added to the reaction was reduced down to 0.2 mg per reaction or the number of sample repetitions was reduced to 2 or 1, or only the sample to which 100 copies of plasmid were added was included to confirm the sensitivity of the PCR assay. Samples that yielded insufficient DNA to conduct the minimal testing of one sample and one sample to which 100 copies of plasmid were added, were not included. Negative controls for the PCR reaction included the reaction mix alone and the empty pNGVL3 plasmid. Products were analyzed on standard agarose gel electrophoresis using ethidium bromide staining and UV light visualization. Faint product bands that were weaker in intensity than that for the sample, to which 100 plasmid copies were added, were counted as positive for the summary Table 1 and for the statistical analysis.
RESULTS
Study design
This study was designed to administer the mIL-12 plasmid to mice using a regimen similar to that proposed for clinical testing to detect any pNGVL3-mIL12 plasmid-derived toxicity and to determine the biodistribution of this therapeutic plasmid throughout the different body compartments. An experimental protocol was chosen that allowed us to determine the biodistribution of the plasmid in a total of 11 tissues. The design of the study is outlined in Figure 1 . To detect possible gender-related distribution and toxicity effects, equal numbers of female and male animals were used for the study: three animals per gender, per time point, per DNA dose. At three different time points, day 25, day 23, and day 21, the three different treatment groups received either PBS, 0.5 mg of plasmid or 5 mg of plasmid. Samples were taken at four time points after the subcutaneous injections of the plasmid: day 0 (24 hr after the day 21 injection), day 14, day 21, and day 28. The tissue samples were taken from each animal in the following sequence. First, the animals were anesthetized and then exsanguinated by retrobulbar bleeding. Second, legs and the head were removed to al-low the bone marrow samples and the brain samples, respectively, to be taken. Third, the gonads were removed, then the other internal organs. Finally, the injection site, which was the skin above the neck area, was removed. This sequence of sample collection, combined with the systematic use of fresh instruments for each group of samples, was chosen to prevent horizontal contamination of plasmid among the samples derived from the same animal. The experiment was conducted in a separate pNGVL3-mIL12 plasmid-free laboratory.
PCR assay
In order to detect pNGVL3-mIL12 plasmid DNA in various tissues and in the blood, we chose to use PCR analysis, the preferred method for the detection of minimal amounts of target DNA in the context of large amounts of genomic DNA (Haworth and Pilling, 2000) . The primers to detect the pNGVL3-mIL12 plasmid but not endogenous mouse IL-12 DNA were designed so that the amplicon included a portion of the cytomegalovirus promoter, a sequence stretch unique to the plasmid, and a portion of the murine p35 unit of the IL12 gene insert. Figure 2 depicts the plasmid with the approximate location of the 784-bp amplicon. Testing of DNA from several different control mouse tissues and murine cell lines revealed no detectable amplicon when these primers were used in a control PCR (data not shown).
The Food and Drug Administration (FDA) requires that the PCR be able to detect a minimal number of 100 copies of any therapeutic plasmid per reaction that contains approximately 1 mg of genomic DNA from the tested tissue. To determine the basic PCR conditions, we first tested serial dilutions of the pNGVL3-mIL12 plasmid diluted in water starting at 10,000 copies down to 10 copies per PCR reaction in 10-fold steps. Although this is not a quantitative assay, Figure 3 shows decreasing PCR product band intensity derived from such a serial dilution of 10,000-10 copies of pNGVL3-mIL12 plasmid. Most importantly, as can be seen in lane 4, 10 copies of pNGVL3-mIL12 plasmid are detectable under the conditions we tested. Based on these findings we were able to proceed to testing actual tissue samples with up to 1 mg of genomic DNA present per PCR reaction.
DNA extraction
In order to determine if the DNA extraction method used for these experiments is able to purify both genomic DNA that is derived from the tissue sample and plasmid DNA that is potentially contained in that same sample, we performed a series of experiments designed to determine the sensitivity of the extraction method. For that purpose, liver tissue samples from naïve mice were mixed with different copy numbers of plasmid prior to the DNA purification process. Then the DNA pu- A: Summary of the polymerase chain reaction (PCR) assay data collected from 48 mice that received repeated injections of pNGLV3-mIL12 plasmid. NIH Swiss outbred female or male mice were injected with either PBS or 0.5 mg or 5 mg of pNGLV3-mIL12 plasmid per animal on day 25, 23, and 21. Tissues were collected on day 0 (24 hr after the injection), on days 14, 21, and 28. For each time point, 3 male and 3 female mice were sacrificed from each group treated with the pNGV3-mIL12 plasmid. Eleven tissues from each individual animal were tested by PCR for the presence of the pNGVL3-mIL12 plasmid. The tissue designation are as follows: BR, brain; BM, bone marow; GO, gonads; KY, kidney; SP, spleen; LI, liver; HT, heart; LU, lung; LN, lymph node; SK, skin; BL, blood. The columns below the tissue designation show the number of animals that tested positive for pNGVL3-mIL12 plasmid per total number of animals tested for that particular tissue and time point. Depending on availability, 0.2-1 mg of sample DNA was tested in triplicate for leach tissue. Only results from DNA samples that did not inhibit the amplification of 100 copies of pNGVL3-mIL12 plasmid spiked into the sample were considered evaluable. In addition, negative results from four mice that received PBS rather than pNGVL3-mIL12 plasmid and were harvested on day 14 are shown. B: Summary of the PCR assay data collected from the repeat study involving 12 mice that received repeated injections of 5 mg of pNGLV3-mIL12 plasmid or PBS. Three mice of each treatment group were sacrificed on day 0 and on day 28. rification was performed and the resulting DNA amplified using the specific primers for the plasmid DNA. Figure 4 , lane 1 shows the amplification product of 100 copies of pNGVL3-mIL12 plasmid that were added into 50 mg of tissue prior to the DNA extraction. As a comparison lane 5 shows the amplification of 100 copies of plasmid that were added into DNA that had already been extracted from a naïve liver tissue sample. As can be seen from the intensity of the bands, there is no apparent reduction in sensitivity of this assay to detect the plasmid when the plasmid is added to tissue samples prior to the DNA extraction, or when the plasmid is added to DNA samples following the DNA extraction. From this we conclude that the DNA purification method used for this study is suitable for the detection of small amounts of plasmid in the context of a large amount of tissue-derived genomic DNA.
Tissue distribution
The next step was to test if the PCR assay was sensitive enough to detect the minimal number of plasmid copies per reaction in the context of 1 mg of DNA, as required by the FDA. Several rounds of PCR with tissue DNA from test animals confirmed the sensitivity of the reaction in that 10 and 100 copies of pNGVL3-mIL12 plasmid per reaction in the presence of 1 mg of genomic DNA were easily detectable (data not shown). We could then proceed to perform the biodistribution study with all the samples that were collected. The PCR assays were performed systematically, testing all the samples from one mouse at a time. This helped to prevent any cross-contamination of samples between animals during the DNA extraction and PCR procedures. Typical outcomes of the PCR testing of different tissues are shown in Figure 5 . As described in the Materials and Methods section, most tissue samples of DNA were tested in triplicate and whenever possible an amount of 1 mg of DNA was added to the PCR reaction. Also, every DNA sample was tested separately with the addition of 1000 and 100 copies of the plasmid, to check the sensitivity of the PCR assay. Figure  5A , 5B, and 5C are representative for the PCR amplification of negative control DNA from animals that received PBS treatment. Lanes 3, 4, and 5 in Figure 5 each represent one of the triplicates tested. The DNA samples derived from the tissues shown in Figure 5A -5E do not inhibit the amplification pNGVL3-mIL12 plasmid added to the DNA, as can be seen in lane 1 (1000 copies of pNGVL3-mIL12 plasmid) and lane 2 (100 copies of pNGVL3-mIL12 plasmid spiked in). Figure 5D shows the detection of pNGVL3-mIL12 plasmid (lanes 3, 4, and 5) in the skin of a female mouse treated with 0.5 mg of pNGVL3-mIL12 plasmid. A weak and barely detectable am- Brain N N N N N N N N N N N N N N N N N N N N N N N N N N N N Bone marrow N N N N N N N N N N N N N N N N N N N N N N N N N N N N Gonads N N N N N N N N N N N N N N N N N N N N N N N N N Tissue samples from all animals were collected, stored in 10% formalin solution, and then fixed and stained with hematoxlyin and eosin for histologic examination. Each tissue sample received one of the following ratings for its histopathology: N, normal organ histopathology; N*, collections of lymphocytes as rests or infiltrates, mild to large accumulations; P, proliferation in follicular centers of spleen.
PBS, phosphate-buffered saline; m, male; f, female.
plification product is depicted in Figure 5E , lanes 3, 4, and 5. The DNA tested here was extracted from the blood of a 0.5-mg plasmid-treated female mouse. The entire collection of the PCR assay data from all 48 plasmid-treated mice, and 4 of 24 control mice tested is summarized in Table 1A . Occasional, erroneous, weak, false-positive PCR results were seen in 20 of the 24 animals that received PBS control injections. Thus all data from these 20 animals were excluded from the analysis. The control animals that are listed in Tables 2, 3 , and 4 are the four control animals that did not show PCR-detectable pNGVL3-mIL12 in the main study. In addition, to confirm the specificity of our assays, a reduced size, repeat biodistribution study was performed. Six male mice were injected intradermally with 5 mg of pNGVL3-mIL12 plasmid and 6 were injected with PBS on day 25, 23, and 21. Day 0 is defined as 24 hr after the last treatment with pNGVL3-mIL12 plasmid. Three mice per group were then sacrificed on day 0 or 28 and the animals evaluated for pNGVL3-mIL12 plasmid in a manner identical to the prior biodistribution study (Table 1A) . In these animals no pNGVL3-mIL12 plasmid was detected at any site in the six control animals. pNGVL3-mIL12 plasmid was again noted in the skin, draining lymph nodes, blood, and occasional other organs of pNGVL3-mIL12-treated animals. These data are summarized in Table 1B . Again no pNGVL3-mIL12 plasmid was detected in the gonads of any animal.
In the 24 mice that received the lower dose treatment of 0.5 mg, the plasmid was not detectable in the spleen and the gonads. A single positive reaction was detected for the brain, the lung, and the lymph node tissues. The injection site skin tissue showed positive detection in 17 of the 24 evaluable mice, with positive reactions throughout the course of the experiment. On day 28 after the injection, 4 of 6 samples from the skin were still positive for the pNGVL3-mIL12 plasmid. The remaining 5 tissues showed 2-4 positive reactions in 18-24 evaluable samples for each tissue type.
In mice that received the high dose treatment (5 mg of pNGVL3-mIL12 plasmid per mouse), no plasmid was detectable in the bone marrow and heart tissue at any time point. One positive signal was detected in the gonads that were taken 24 hr after the high-dose injection. No plasmid was detected in the gonads anytime after the 24-hr time point. When looking at the different time points we observed that at the day 0 time point, there is a statistically significant (t test, p 5 0.01) difference between low-dose (8 positive) and the high-dose (19 positive) treatments. This indicates that dissemination of the plasmid is happening and that a higher dose treatment results in a greater dissemination than a lower dose treatment. We were able to detect this difference only at the day 0 time point, 24 hr after the last injection was done. Analysis of the later time points did not reveal a detectable difference between the treatment doses.
There was no significant difference in the distribution pattern of detectable plasmid between male and female mice of the low-or high-dose treatment (not shown). 
Histopathology
In order to detect any pNGVL3-mIL12 plasmid treatmentrelated effects on the cellular level, histology was performed with all the samples taken. Table 2 shows the summary of the histology data. No treatment related differences were noted between the control animals and the two different treatment groups. There were lymphocytic infiltrates detectable in the livers of several female animals without evidence of other histologic abnormalities. These lymphocytic infiltrates were observed in females of control and treatment groups and as such not attributable to the pNGVL3-mIL12 plasmid treatment. Also, centers of proliferation were noted in the spleen of a number of female animals from all three treatment groups and thus not related to the pNGVL3-mIL12 plasmid therapy. These areas of lymphocytic infiltrate or proliferation, which were observed exclusively in treated and control female animals, likely reflects the advanced age of these female mice. From these histologic observations we conclude that the pNGVL3-mIL12 plasmid treatment does not cause any detectable histopathology in mice. Table 3 shows the results of ELISA testing. The preclinical efficacy studies that the clinical protocol for the IL-12 gene therapy is based on utilized a 10-to 100-fold higher dose of the pNGVL mIL-12 plasmid (50 mg per animal per day) than the 0.5-5.0 mg per animal per day used here. By extrapolation (based on these preclinical studies) we expected 100 to 400 pg IL-12 protein in the treatment site at the 5 mg pNGVL3-mIL12 dose (group 3). The lower limit of detection of our IL-12 ELISA assay was 300 pg. We thus did not expect to detect the IL-12 protein in the treatment site. Furthermore, we did not detect augmented IL-12 protein in the serum of treated mice in our previous preclinical studies (unpublished data), and thus did not expect to detect a difference n serum IL-12 levels between control and treated mice at these doses. There were, however, nontreatment-related differences noted between genders (Table 3) when values from male mice from all time points and treatment groups are compared to the values for all female mice. The female mice had significantly higher levels of IL-12 in the plasma than the male mice (p , 0.001). The female mice also had statistically significantly higher levels of IL-12 in the tissue than the male mice (p , 0.001). The female mice had statistically significantly lower levels of IFN-g in the tissue than the male mice (p 5 0.002).
IL-12 and IFN-g levels
The tissue IFN-g level decreased in both male and female animals with increasing days posttreatment (Table 3) , and the observed decrease was statistically significant (p 5 0.002). No treatment related effect was detected. The amount of protein per site was never greater than 1000 pg. The amount of IFN-g protein (when detected) was similar to the lower level of sensitivity of the assay (300 pg). In summary, the protein detection data presented in Table 3 indicate that there was no significant treatment related change in the tissue or plasma level of either IL-12 or IFN-g.
Clinical chemistry and hematology values
The toxicities noted in preclinical and clinical IL-12 protein studies have been hepatic, hematologic, and renal. We therefore focused on these organ systems. Blood was collected from three animals per gender, per treatment group, per time point (0, 14, 21, and 28) and evaluated for alanine transferase (ALT), aspartate transferase (AST), bilirubin, hemoglobin, white blood cell count, platelets, creatinine, blood urea nitrogen (BUN), and glucose (Table 4 ). The only treatment-related change was a dose-related increase in serum glucose. The glucose level increased with the increasing dose, and the observed increase was SAFETY OF IL-12 GENE THERAPY 1043
FIG. 2.
Plasmid map of pNGVL3-mIL12. The amplicon (784 bp) generated by the primers designed to amplify the plasmid specific and interleukin (IL)-12 gene specific sequence is shown in black. The location and the size of the amplicon are an approximation. The plasmid was designed by the National Gene Vector Laboratory, University of Michigan, Ann Arbor, MI. The plasmid is described in detail in the Materials and Methods section.
FIG. 3.
Sensitivity testing of optimal polymerase chain reaction (PCR) conditions for the amplification of the pNGVL3-mIL12 plasmid. Various copy numbers of pNGVL3-mIL12 plasmid were added to the PCR reaction mix and the reaction was performed under standard conditions. Lane 1 shows the signal intensity when 10,000 copies of pNGVL3-mIL12 plasmid were added to the reaction; lane 2, when 1000 copies of pNGVL3-mIL12 plasmid were added; lane 3, when 100 copies of pNGVL3-mIL12 plasmid were added; and lane 4, when 10 copies of pNGVL3-mIL12 plasmid were added to the reaction. Amplification products were separated by agarose gel electrophoresis and subsequently stained with ethidium bromide to allow visualization under UV light.
significant with p 5 0.04. Several differences in laboratory values that were not related to treatment achieved statistical significance. The female mice had significantly lower bilirubin levels than the male mice (p 5 0.014). The female mice had significantly lower levels of BUN than the male mice (p , 0.001). The female mice had statistically lower platelet counts than the male mice (p , 0.001). The female mice had significantly higher ALT levels than the male mice (p 5 0.001). The female mice had significantly lower glucose levels than the male mice (p 5 0.014). The platelet count decreased (both male and female animals) with increasing days posttreatment, and the observed decrease was statistically significant (p , 0.001). This was not related to treatment. The only treatment-related change thus was an increase in serum glucose that was doserelated. The magnitude of the change suggests that this is not clinically relevant. No other treatment-related toxicity was detected.
DISCUSSION
Prior to the performance of a human clinical trial using intratumorally injected IL-12 gene therapy, a murine biodistribution and safety study was designed to mimic the clinical trial. For this study, the pNGVL3-mIL12 plasmid was used. This construct is virtually identical to the plasmid for the proposed human trial (pNGVL3-hIL12) except that the IL-12 gene insert, composed of the p35 and the p40 subunits, is murine rather than human. The experiments presented here were designed to assess the biodistribution and the safety of intradermally administered pNGVL3-mIL12 plasmid in mice. The pNGVL3-mIL12 plasmid was given to male and female mice in a treatment regimen that resembles the proposed clinical trial but at 400-4000 times higher doses relative to the body weight. This relative overdose of the plasmid given to mice ensured that any treatment-related side effects and toxicities should be intensified and therefore more likely to be detected by this safety study. In addition, it was expected that an overdose of plasmid should result in an intensified distribution throughout the body of the mouse in comparison to that expected for our clinical trial. This should allow this preclinical study to cautiously overestimate the likelihood of invasion of the reproductive organs by the plasmid in a future clinical trial.
The PCR monitoring of the plasmid distribution revealed that the plasmid was detectable throughout the two studies in 39 of 54 samples (72%) of all the skin samples (injection site) that received either the low-dose (0.5 mg) or the high dose (5 mg) treatment. The persistence of a therapeutic plasmid at the injection site was expected and reported earlier in similar studies performed with intramuscular (Parker et al., 1999) and intradermal injections of naked DNA (Harvey et al., 1999) . The second highest percentage of tissue samples found positive for the presence of the pNGVL3-mIL12 plasmid was the blood, with 10 of 40 evaluable samples (25%) positive. At the 24-hr time point, 7 of 10 evaluable specimens of the blood were positive. In contrast, only 3 of 30 evaluable specimens were positive in the blood at later times. This indicates that detectable plasmid is transiently found in the circulation. This result confirms a prior report that the half-life of the plasmid in the circulation is relatively short (Parker et al., 1999) .
Approximately 14% of the evaluable lymph node samples, 13% of the evaluable kidney samples, and 12% of the evaluable brain samples tested positive for the plasmid. All other tissues showed detectable plasmid in less than 10% of the samples.
In summary, of the 543 evaluable tissue samples from the 54 plasmid-treated mice included in the data presented above, 86 tissues tested positive for the pNGVL3-mIL12 plasmid, indicating that the plasmid can only be detected in approximately 16% of the tissues. There was no significant difference in the number of positive tissues detected among the low-dose versus the high-dose treated animals. Among the 54 animals that received the therapeutic plasmid, there were 11 animals from both genders that did not show any detectable pNGVL3-mIL12 plasmid in any of their tissues. Of these, 6 animals belonged to the low-dose treatment group and 5 animals to the high-dose treatment group. This suggests that the higher dose of plasmid given to the animals did not result in a higher level of distribution detectable throughout the body. Although this is somewhat unexpected, it might reflect the limitations of the intradermal route of administration in bringing significant amounts of plasmid into circulation. This could potentially be an advantage of the intradermal route of administration because it might allow escalation of the dose of therapeutic plasmid in patients without significantly increasing the systemic exposure to the plasmid.
Most importantly, the IL-12 plasmid could not be detected in any of the gonads of the animals tested at a time point later than 24 hr after the treatment. Only 1 animal from the highdose treatment group at the 24-hr time point tested positive in FIG. 4 . Polymerase chain reaction (PCR) amplification of pNGVL3-mIL12 plasmid mixed with tissue prior to DNA extraction. Different numbers of pNGVL3-mIL12 plasmid were added to approximately 50 mg of liver tissue from a naïve mouse that was subsequently subjected to the DNA extraction procedure. The resulting DNA from the extraction was tested for pNGVL3-mIL12 plasmid by PCR. Lane 1, amplification product from a sample to which 100 copies of pNGVL3-mIL12 plasmid was added prior to DNA extraction. Lane 2, amplification product from liver sample that had 500 copies of pNGVL3-mIL12 plasmid added prior to DNA extraction. Lane 3, amplification product from a liver sample that had 1000 copies of pNGVL3-mIL12 plasmid added prior to DNA extraction. Lane 4, control amplification of DNA extracted from the same liver tissue without any pNGVL3-mIL12 plasmid added. Lane 5, amplification of control DNA that was mixed with 100 copies of pNGVL3-mIL12 plasmid after the DNA was extracted. Lane 6, amplification of control DNA that was mixed with 1000 copies of pNGVL3-mIL12 plasmid after the DNA extraction. the gonads. From the high-dose treated animals tested 24 hr after the treatment, 4 of 5 animals tested positive for the plasmid in their blood. Thus the positive signal found in the gonads of this one animal could have been derived from plasmid that was circulating with the blood through the gonads.
In the toxicity study, we did not detect any treatment-related toxicities nor any treatment related levels of either IL-12 or IFN-g. This was not surprising. We detected significant increases in IL-12 protein at the injection site only after 50 mg of pNGVL3-mIL12 plasmid was used to treat the mice. At this 50-mg dose, we achieved a strong antitumor effect in our CT-26 intradermal tumor model (unpublished observations). Even though the dose used in our preclinical antitumor treatment model is 10 times higher than the 5-mg dose used in this study, the animals receiving 50 mg pNGVL3-mIL12 did not show any treatment-related toxicities or impact on their normal behavior, based on clinical observation (data not shown).
The present study here was designed to fulfill the requirements of the FDA for the use of a therapeutic plasmid in a human clinical phase I trial. The goal was to demonstrate that the pNGVL3-mIL12 plasmid is safe, does not induce significant toxicities, and does not impose the threat of a horizontal gene transfer into cells of the reproductive organs. The data presented here demonstrate that even at a 4000 times higher dose per kilogram than the dose planned to be given to human patients, the plasmid is safe and does not induce any toxicities in mice. In , and (C) were considered negative. D: Assay of DNA derived from the skin of a female mouse treated with 0.5 mg of pNGVL3-mIL12 plasmid harvested on day 0. This sample was considered positive. E: DNA derived from the blood of a female mouse treated with 0.5 mg of pNGVL3-mIL12 plasmid harvested on day 0. This sample was considered positive although the intensity of the product band was weaker than the product band for the sample, which had 100 copies of the plasmid, added (lane 2). F: lane 1, 100 copies of pNGVL3-mIL12 plasmid and lane 2, 1000 copies of pNGVL3-mIL12 plasmid tested in the absence of sample DNA. F: lane 5, negative control test of PCR mix alone. The bands visible below the amplification products in A-F are unspecific byproducts observed throughout all reactions. sample from a total of 500 ml supernatant that was collected as described in the Materials and Methods section.
